An integrated action plan to fund and support drug development for Dup15q syndrome: a patient organization perspective

Ther Adv Rare Dis. 2024 Mar 5:5:26330040241234932. doi: 10.1177/26330040241234932. eCollection 2024 Jan-Dec.

Abstract

Maternal 15q11.2-13.1 duplication syndrome, or Dup15q syndrome (Dup15q), is a rare neurodevelopmental disorder affecting as many as 1 in 5000 to 1 in 20,000 children worldwide. Autism and seizures are two of the most commonly observed phenotypes in Dup15q, with intellectual disability, hypotonia, gastrointestinal distress, and substantial fine and gross motor deficits also commonly reported. The community that is now known as the Dup15q Alliance started in 1994 as a small group of families raising children with chromosome 15q duplications. Originally named IsoDicentric 15 Exchange, Advocacy and Support (IDEAS), the group received official nonprofit organization status 10 years later and rebranded to its current name, Dup15q Alliance, shortly thereafter. Today, there are over 2200 families affiliated with Dup15q Alliance, with an average intake of 10 new families each month. Historically, Dup15q Alliance has provided the community with access to family and caregiver resources in addition to serving as a repository for basic educational information about Dup15q and research developments. The recent installation of a dedicated director of scientific and clinical initiatives alongside other infrastructural changes has now primed the Dup15q Alliance to expand its scientific footprint by funding cutting-edge research, supporting clinical sites and trials, and investing in novel therapeutics that have the potential to change the reality of a Dup15q syndrome diagnosis. To do this, we have developed the LEARN. TREAT. CURE. program to align initiatives, fast-track progress, and bring hope and reality into coexistence. Briefly, we seek to learn as much as we can about the syndrome through cutting-edge research, natural history studies, and patient registry utilization, identify and develop methods to treat the symptoms of our patient community, with the ultimate goal of developing a cure for the disease-causing symptoms of the syndrome.

Keywords: Dup15q syndrome; collaboration; community; registry; scientific initiatives.

Plain language summary

A campaign to accelerate drug discovery in Dup15q Syndrome Patient advocacy groups aid in raising awareness and funding for specific disorders. Nearly three decades ago, Dup15q Alliance was founded by parents of individuals with maternal Duplication 15q Syndrome. This group has grown significantly and is now focused on funding programs to advance research. To do this, they have revised their infrastructure to include a part-time Director of Scientific and Clinical Initiatives and developed a fundraising campaign dedicated to scientific and clinical programming. They also emphasize collaboration and community engagement as key elements of the campaign.